NEW YORK and COPENHAGEN-October 5, 2017-Medidata (NASDAQ: MDSO), a global provider of cloud-based solutions and data analytics for clinical research, today announced that pharmaceutical firm H. Lundbeck A/S (Lundbeck), has entered a multi-year partnership to continue its use of the Medidata Clinical Cloud® and utilize operational capabilities to power their next generation global clinical trials. The continued partnership allows Lundbeck to leverage integral parts of the Medidata Clinical Cloud platform that provide key capabilities in study conduct and site support, including Medidata Rave®, Coder®, and TSDV (Targeted Source Document Verification). A Medidata customer since 2007, Lundbeck is a global pharmaceutical company specializing in psychiatric and neurological disorders. By continuing its use of Medidata Rave®, a industry solution for capturing, managing, and reporting data, Coder®, and TSDV (Targeted Source Document Verification), Lundbeck will increase the quality of its clinical research efforts by more accurately evaluating clinical data, streamlining workflows, and ultimately, optimizing trial results. “We’re proud to be a long term partner to Lundbeck, an innovative organization bringing together deep industry expertise in drug development activities for neurological disorders,” said Mike Capone, chief operating officer at Medidata. “We look forward to continuing to power their mission to tackle unmet needs for patients living with serious medical conditions.”
About Medidata
Medidata is reinventing global drug and medical device development by creating the industry's leading cloud-based solutions for clinical research. Through our advanced applications and intelligent data analytics, Medidata helps advance the scientific goals of life sciences customers worldwide, including over 850 global pharmaceutical companies, biotech, diagnostic and device firms, leading academic medical centers, and contract research organizations.
The Medidata Clinical Cloud® brings a new level of quality and efficiency to clinical trials that empower our customers to make more informed decisions earlier and faster. Our unparalleled clinical trial data assets provide deep insights that pave the way for future growth. The Medidata Clinical Cloud is the primary technology solution powering clinical trials for 18 of the world's top 25 global pharmaceutical companies and is used by 18 of the top 25 medical device developers-from study design and planning through execution, management and reporting. Medidata Contacts Investor: Anthony D’Amico, Medidata Solutions, +1 732-767-4331,
adamico@mdsol.com
Media: Erik Snider, Medidata Solutions, +1 646-362-2997,
esnider@mdsol.com
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.